Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Hematology
Link
http://link.springer.com/article/10.1007/BF02986620/fulltext.html
Reference40 articles.
1. Devita VT Jr, Serpick AA, Carbone PP. Combination chemo- therapy in the treatment of advanced Hodgkin’s disease.Ann Intern Med. 1970;73:881–895.
2. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease.J Clin Oncol. 1986;4:1295–1306.
3. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.Cancer. 1975;36:252–259.
4. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross- resistant combination chemotherapy or MOPP in stage IV Hodg- kin’s disease: a report of 8-year results.Ann Intern Med. 1986;104: 739–746.
5. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alter- nating with ABVD.N Engl J Med. 1992;327:1478–1484.
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Successful Pregnancy and Fetal Outcomes Following Brentuximab Vedotin for Early Relapsed Classic Hodgkin Lymphoma After Autologous Stem Cell Transplant;Cureus;2024-03-30
2. A case of peripheral T-cell lymphoma in which therapy-related myelodysplastic syndrome developed and a second autologous transplantation was performed;Journal of Clinical and Experimental Hematopathology;2024
3. Adverse impact of delay of platelet recovery after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma and multiple myeloma;Cytotherapy;2023-11
4. Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study;Cancer Medicine;2023-08-28
5. Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients;Expert Review of Anticancer Therapy;2021-03-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3